Literature DB >> 33849528

Influence of icariin on inflammation, apoptosis, invasion, and tumor immunity in cervical cancer by reducing the TLR4/MyD88/NF-κB and Wnt/β-catenin pathways.

Chunyang Li1, Shuangqing Yang2, Huaqing Ma2, Mengjia Ruan2, Luyan Fang2, Jing Cheng3.   

Abstract

BACKGROUND: Cervical cancer is a type of the most common gynecology tumor in women of the whole world. Accumulating data have shown that icariin (ICA), a natural compound, has anti-cancer activity in different cancers, including cervical cancer. The study aimed to reveal the antitumor effects and the possible underlying mechanism of ICA in U14 tumor-bearing mice and SiHa cells.
METHODS: The antitumor effects of ICA were investigated in vivo and in vitro. The expression of TLR4/MyD88/NF-κB and Wnt/β-catenin signaling pathways were evaluated.
RESULTS: We found that ICA significantly suppressed tumor tissue growth and SiHa cells viability in a dose-dependent manner. Also, ICA enhanced the anti-tumor humoral immunity in vivo. Moreover, ICA significantly improved the composition of the microbiota in mice models. Additionally, the results clarified that ICA significantly inhibited the migration, invasion capacity, and expression levels of TGF-β1, TNF-α, IL-6, IL-17A, IL-10 in SiHa cells. Meanwhile, ICA was revealed to promote the apoptosis of cervical cancer cells by down-regulating Ki67, survivin, Bcl-2, c-Myc, and up-regulating P16, P53, Bax levels in vivo and in vitro. For the part of mechanism exploration, we showed that ICA inhibits the inflammation, proliferation, migration, and invasion, as well as promotes apoptosis and immunity in cervical cancer through impairment of TLR4/MyD88/NF-κB and Wnt/β-catenin pathways.
CONCLUSIONS: Taken together, ICA could be a potential supplementary agent for cervical cancer treatment.

Entities:  

Keywords:  Cervical cancer; Icariin; Inflammation; Microbiota; Tumor immunity

Year:  2021        PMID: 33849528     DOI: 10.1186/s12935-021-01910-2

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  5 in total

1.  Icariin inhibits the growth of human cervical cancer cells by inducing apoptosis and autophagy by targeting mTOR/PI3K/AKT signalling pathway.

Authors:  Shenjiao Huang; Tingting Xie; Wenjie Liu
Journal:  J BUON       Date:  2019 May-Jun       Impact factor: 2.533

2.  IFN-γ +874 T/A polymorphisms contributes to cervical cancer susceptibility: a meta-analysis.

Authors:  Nannan Liu; Yan Song; Weifeng Shi
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Flavonoids from Scutellaria barbata inhibit activation of tumor-associated macrophages by blocking the Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB signaling pathway.

Authors:  Xiaoxia Bao; Liuye Li; Xiaoou Xue
Journal:  J Tradit Chin Med       Date:  2019-04       Impact factor: 0.848

4.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

5.  Immunomodulatory effect of Schisandra polysaccharides in cyclophosphamide-induced immunocompromised mice.

Authors:  Jiahui Yu; Lixin Cong; Chunmei Wang; He Li; Chengyi Zhang; Xingang Guan; Peng Liu; Yu Xie; Jianguang Chen; Jinghui Sun
Journal:  Exp Ther Med       Date:  2018-04-16       Impact factor: 2.447

  5 in total
  3 in total

1.  Current update on anticancer effects of icariin: A journey of the last ten years.

Authors:  Mukta Gupta; Yachana Mishra; Vijay Mishra; Murtaza M Tambuwala
Journal:  EXCLI J       Date:  2022-04-06       Impact factor: 4.022

Review 2.  Biophysics involved in the process of tumor immune escape.

Authors:  Maonan Wang; Hui Jiang; Xiaohui Liu; Xuemei Wang
Journal:  iScience       Date:  2022-03-19

3.  Icariin attenuates the tumor growth by targeting miR-1-3p/TNKS2/Wnt/β-catenin signaling axis in ovarian cancer.

Authors:  Yanjin Fu; Haiquan Liu; Mengsha Long; Linliang Song; Zuyu Meng; Shaozi Lin; Yiyao Zhang; JiaJia Qin
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.